Reassessing prognostic markers in metastatic renal cell carcinoma in the era of immune checkpoint inhibitors: the enduring value of body composition, nutritional, and inflammatory indices.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) are now the standard first-line treatment for metastatic renal cell carcinoma (mRCC), yet many risk factors identified during the tyrosine kinase inhibitor era remain unvalidated in current practice. This study aimed to evaluate the prognostic value of body composition, nutritional, and inflammatory indices in the era of ICI-based first-line therapy.

Methods

We retrospectively analyzed 136 mRCC patients who received systemic therapy. Body composition indices (skeletal muscle index [SMI], visceral adipose tissue index [VATI], subcutaneous adipose tissue index [SATI]), nutritional markers (prognostic nutritional index [PNI], geriatric nutritional risk index [GNRI]), and inflammatory markers (Glasgow Prognostic Score [GPS], systemi

SUBMITTER: Tsuchiya N 

PROVIDER: S-EPMC12932366 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature